Severe thrombocytopenia (platelets <50 × 10 9
thrombocytopenia (<50 × 10 9 /L) on prognosis of these patients. 14, 15 Little is known about the impact of severe thrombocytopenia on the outcome of patients with PMF vs PPV-MF vs PET-MF, which we have aimed to evaluate here.
| METHOD
In a retrospective cohort analysis, we evaluated the clinical characteristics, therapy, and outcome in patients with MF (separately for PMF, T A B L E 1 Demographics and clinical characteristics of patients stratified based on platelet count PPV-MF 212 (17) 17 (12) 32 (18) 163 (17) PET-MF 180 (14) 10 (7) 7 (4) 163 (17) Males, N (%) All statistical computations were performed using SPSS, version 24.0 (Chicago, IL). The study was conducted using retrospective chart review protocol approved by institutional review board. Table 1 , and comparison between plt 50 and plt 50-100 groups stratified by diagnosis in Table 2 . Patients with PET-MF were represented more frequently in the group with plt 100; however, this was not statistically significant, and the overall distribution of patients with different diagnoses and platelet counts was similar ( Figure S1 ).
| RESULTS

Among
Median platelet count in these groups (plt 50, plt 50-100 and plt 100) was 27 (range, 1-50), 77 (range, 52-100), and 278 (range, 101-2690), respectively. In general, plt 50 group was older and had highest rate of anemia, transfusion dependency, blood and bone marrow blasts, unfavorable and complex (3 or more abnormalities) karyotype, and the highest rate of progression to acute leukemia (AML) ( Tables 1   and 2, and Table S1 ). Subanalysis of patients with low platelets (plt 50
and plt 50-100) stratified by diagnosis ( Table 2 ), revealed that patients with PPV-MF had the highest white cell counts in both groups, while those with PMF and plt 50 were most anemic and had the largest spleen. Other clinical features did not differ among groups.
In regards to therapy, 15% (n = 185) of patients were not treated for their disease during their follow-up. Among those treated (n = 1084), 55% (n = 593) received one or two therapies, most often hydroxyurea (n = 501), immunomodulatory agents (n = 261), and JAK2 inhibitor ruxolitinib (n = 328). Overall, 96 patients (8%) underwent allogeneic SCT with similar proportional distribution among groups (73 PMF: plt <50 and 50-100 in 9 and 15 patients; 9 PPV-MF: plt < 50 and 50-100 in 1 and 2; 14 PET-MF: plt < 50 in 1 patient; respectively).
Among patient exposed to ruxolitinib, only 3% and 10% (n = 11
and n = 32) were in plt 50 and plt 50-100 groups, respectively, which was significantly lower than for plt 100 group (87%, n = 285; both P < .005).
The overall median follow-up time from presentation to our institution was 27 months (range, 5-251) and was the shortest for plt 50 group (12 months, P < .001). Median OS for plt 50 vs plt 50-100 vs plt 100 groups was 15 vs 44 vs 57 months, respectively (P < .001, Subanalysis of newly diagnosed patients (n = 678) confirmed this observation, with OS for plt 50 vs plt 50-100 vs plt 100 groups of 15, 44, and 64 months, respectively (P < .001, Table S2 ). We also compared survival difference between patients with plt above and below 100 (combined patients with plt 50 and plt 50-100). The OS of patients with plt below 100 was inferior to those with plt above 100 with 1.7-fold increased risk of death (26 vs 57 months, P < .001, HR 1.7
(95% CI 1.37-2).
Analyses of OS for patients with PMF, PPT-MF, and PET-MF within the same plt group showed differences among patients with plt 50 and plt 100. PET-MF patients had the shortest OS in plt 50 group (PMF vs PPV-MF vs PET-MF; median OS = 15 vs 20 vs 6 months, respectively; P = .003), but the longest in plt 100 group (50 vs 64 vs 79 months, P < .001). No difference was noticed among those with plt 50-100 group (44 vs 36 vs 36 months, P = .63, Table S2 , graphs not shown).
Analyses of OS based on plt level within each disease entity showed differences. Among PMF patients, plt 50 had significantly worse OS than all others, but OS for plt 50-100 was similar to plt 100 (15 vs 44 vs 50 months, respectively, overall P < .001; but P = .36 for plt 50-100 vs plt 100; Figure 2A ). Survival censored for SCT confirmed our findings with respective OS of 13 vs 31 vs 47 months (plt 50 vs 50-100 vs 100; data not shown).
Similar results were found when OS was adjusted per International Prognostic Scoring System or Dynamic International Prognostic
Scoring System risk scores in newly diagnosed or all patients, respectively (Table S2) .
Further stratification of patients with PPV-MF and PET-MF showed them to have inferior OS once their platelets drops below 100 (plt 50-100 vs plt 100, P < .001 for both groups, Figure Subanalysis including only newly diagnosed patients confirmed our above observations with only one exception: Among PET-MF patients, both plt 50 and plt 50-100 had very poor OS (6 months for both groups, Table S3 ).
During an observation period of 3849 person-years, 140 (11%) patients had progressed to AML, with an incidence of 3.6 cases per 100 person-years. The incidence of AML in plt 50-100 and plt 100 groups was similar to overall incidence (3.6 and 3.4 cases per 100 person-years, respectively). However, incidence of AML was almost doubled in plt 50 group (6.9 cases per 100 person-years). In line with this results, leukemiafree survival (LFS) was the shortest in plt 50 group: median LFS for plt 50 vs plt 50-100 vs plt 100 groups was 13 vs 34 vs 52 months, respectively (P < .001, Figure 3 ). LFS at one year (plt 50 vs plt 50-100 vs plt 100) was 55% vs 78% vs 85%, and at 3 years 23% vs 48% vs 61%, respectively.
When stratified according to the diagnosis, the shortest LFS was seen in patients with PET-MF and plt 50 (6 months), and the longest in PET-MF and plt 100 (76 months). During the entire follow-up, 51% (n = 652) patients died, with the highest rate among those with plt 50 (plt 50 vs plt 50-100 vs plt 100: 70% vs 55% vs 48%, respectively).
| DISCUSSION
Thrombocytopenia (platelets <100 × 10 9 /L) is seen in patients with MF, with an overall incidence around 26%. 1 Severe thrombocytopenia Blasts BP 10-19%, N (%) 9 (7) 0 1 (10) 5 (4) 3 (9) 1 (14) AML transformation, N (%) 13 (11) 0 4 (40) 13 (10) 3 (9) 1 (14) DIPSS score, N (%) Hernandez and colleagues 15 reported on a group of 57 patients with severe thrombocytopenia (41 PMF, 16 PET/PPV-MF) that had adverse clinical features, such as higher age, lower hemoglobin and absolute neutrophil count, higher blasts and higher fibrosis, higher DIPSS risk score, more cytogenetic abnormalities, as well as higher progression rate to AML, than other patients, with a median survival of 2.2 years.
Our study confirmed the adverse clinical features as well as poor OS and LFS in these patients in the largest cohort of patients reported so far. Furthermore, we compared the impact of low platelets on the outcome of patients with PMF vs PPV-MF vs PET-MF, as it has been shown that these patients differ in their clinical characteristics and OS. 24 Similar to what was reported by Hernandez et al, we found that plt 50 group is the most anemic and transfusion dependent, but this was mostly present in those with PMF. While plt 50 group had the highest blast count and unfavorable karyotype, the highest progression rate to AML was seen in those with PET-MF and plt 50. On the other hand,
PET-MF patients in plt 100 group had the longest OS and LFS. In contrast to results published by Hernandez et al, 15 we did not find the highest rate of high DIPSS score, lower neutropenia, and higher fibrosis grade in plt 50 group, vs others, nor were these patients the oldest. Treatment with specific therapy such as JAK2 inhibitor, ruxolitinib, was observed in minority of patients with platelets below 100, which is in line with previous reports. Although JAK2 inhibitors are not approved for patients with severe thrombocytopenia, there are case reports and series in which JAK2 inhibitors have been used successfully with improvement of platelet count. 25, 26 However, for the majority of patients, the management of severe thrombocytopenia remains an unmet need, and future studies focused on patients with low platelets are deeply needed, to extend their extremely limited treatment armamentarium. Consequently, allogeneic stem cell transplantation should be offered to all eligible patients to alter the disease course.
A major limitation of our study is its retrospective character, data from a single center, and limited number of patients in subanalyses. A large, prospective, multicenter study should be performed to improve our understanding of the biology of the disease and identify the most reliable factors and signs of progression. 
